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Background: The intracellular mechanisms involved in the activation of DCs during
sensitization in allergic contact dermatitis (ACD) are not known.
Objective: Here, we investigated the effect of a strong sensitizer, 2,4-dinitrofluor-
obenzene (DNFB) on the activity of MAPKs in a dendritic cell (DC) line generated from
fetal mouse skin (FSDC), and the results were correlated with the expression of a
costimulatory molecule upregulated upon DC maturation, CD40.
Methods: Phosphorylation of ERK1/2 (pERK1/2) and p38 MAPK (pp38 MAPK),
and CD40 protein levels, were determined by Western blot. Cellular localization of
pERK1/2 and pp38 MAPK were determined by immunocytochemistry using phospho-
specific antibodies.
Results: Although with different kinetics, DNFB activated ERK1/2 and p38 MAPK, and
induced the translocation of the phosphorylated forms of the kinases to the nucleus.
In addition, DNFB upregulated significantly CD40 protein levels in FSDC. However, 2,4-
dichloronitrobenzene (DCNB), an inactive analogue of DNFB, did not affect signifi-
cantly the phosphorylation of MAPKs and CD40 protein levels. SB203580 and SB202190,
inhibitors of the p38 MAPK activity, inhibited DNFB-induced CD40 upregulation,
although this effect did not reach statistical significance. In contrast, PD 98059
and U0126, inhibitors of mitogen or extracellular signal-regulated kinase (MEK),
had no effect on the CD40 upregulation induced by DNFB.* Corresponding author. Tel.: +351 239 480209; fax: +351 239 480208.
E-mail address: cbduarte@ci.uc.pt (C.B. Duarte).
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Conclusions: Taken together, these results indicate that the strong sensitizer DNFB
activates ERK1/2 and p38 MAPK signaling pathways, and upregulates CD40 protein
levels. However, MAPKs do not play a major role in the induction of CD40, one of the
phenotypic markers of DC maturation.
# 2005 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland
Ltd. All rights reserved.1. Introduction
Allergic contact dermatitis (ACD), one of the most
common inflammatory skin disorders [1,2], is a
delayed-type hypersensitivity reaction caused by
a wide range of low molecular weight reactive
chemicals (haptens). These haptens enter the skin
and bind self-proteins, converting them into immu-
nogenic peptides that are captured and processed
by dendritic cells (DCs) [1,3—5]. Skin DC, when
activated by inflammatory stimuli or by haptens
loose their antigen uptake and processing capacity
and acquire professional antigen presenting capa-
city [1]. For this process, DCs switch chemokine
receptors and cytokine synthesis, and upregulate
the expression of major histocompability complex
(MHC) molecules, and adhesion and costimulatory
molecules (CD80, CD86, CD83, CD40) [6—10].
Several skin sensitizers have been shown to upre-
gulate DC expression of CD40, namely 2,4,6-trini-
trobenzene sulfonic acid (TNBS), aminophenol,
chlorpromazine hydrochloride, dinitrochloroben-
zene (DNCB) and the metal allergen nickel sulfate
[11,12]. CD40, a member of the tumor necrosis
factor receptor (TNFR) family, is a 45—50 kDa recep-
tor expressed on a wide range of cell types, includ-
ing B cells, macrophages and DCs [13,14]. During
antigen presentation, the interaction of CD40 in DCs
with its ligand (CD40L) on activated Tcells is critical
for DC maturation and induces Interleukin-12 (IL-12)
production, leading to differentiation of Tcells into
T helper type1 (Th1) [15,16].
The exact cellular and molecular mechanisms of
DC activation by haptens remain unclear. An
increased phosphorylation of tyrosine residues in
murine LCs and human MHC class II positive antigen
presenting cells (APC) has been detected upon sti-
mulation with contact sensitizers [17,18], suggest-
ing that activation of protein tyrosine kinases is
involved in contact sensitization. Enzymes belong-
ing to the family of MAPKs are strong candidates for
activating effector proteins, since they propagate
signals generated from different stimuli and have a
multiplicity of signal transducing functions, con-
verting extracellular signals into intracellular
responses. Three major genetically distinct MAPK
pathways are known at present in mammals: the
extracellular signal-regulated kinases (ERKs), c-JunNH2-terminal kinases (JNKs) and the p38 high osmo-
larity glycerol protein kinase (p38 MAPKs). Each
MAPK is positioned at the bottom of a distinct kinase
pathway composed of three sequential dual specific
kinases [19—23]. Activated MAPKs can translocate
into the nucleus where they may phosphorylate
substrates such as transcription factors [22,24—
27]. TNFa and LPS activate p38 MAPK in DCs [28],
and Chemical sensitizers also increase p38 MAPK
activity, or p38 MAPK and ERK1/2 activity, in human
monocyte derived DCs [29—31] and in a BC1 cell line
(an immature DC cell line) [32].
In order to clarify some of the signaling events
involved in the sensitization phase of ACD and in DC
maturation, we investigated MAPK activation and
their putative role in CD40 expression, upon sensi-
tization of a fetal skin dendritic cell line (FSDC)
representative of early DC precursors [33]. The
effect of a strong sensitizer, 2,4-dinitrofluoroben-
zene (DNFB), and its inactive analogue, 2,4-diclor-
onitrobenzene (DCNB), were compared.2. Materials and methods
2.1. Reagents
Trypsin was purchased from Invitrogen GIBCO (Pais-
ley, UK). Fetal calf serum was from Biochrom (Ber-
lin, Germany). The 2,4-dinitrofluorobenzene
(DNFB) and 2,4-dichloronitrofluorobenzene (DCNB)
were obtained from Aldrich (Madrid, Spain). Anti-
bodies against phospho-ERK 1/2 and phospho-JNK
were obtained from Promega (Madison, WI). The
anti-phospho-p38 MAPK antibody was from Cell
Signaling Technology (Beverly, MA). Anti-CD40 anti-
body was purchased from R&D Systems (Minneapo-
lis, MN). The alkaline phosphatase linked goat anti-
rabbit IgG (H + L) antibody and the ECF substrate
were purchased from Amersham Biosciences (Car-
naxide, Portugal) and the alkaline phosphatase
linked goat anti-rat IgG (H + L) antibody was pur-
chased from Chemicon (Temecula, CA). Alexa 488-
conjugated goat anti-rabbit antibody and the Pro-
long Antifade kit were from Molecular Probes Eur-
ope (Leiden, The Netherlands), and the normal goat
serumwas fromZymed Laboratories (San Francisco,
CA). All other reagents were obtained from Sigma
DNFB activates MAPKs and upregulates CD40 in skin-derived dendritic cells 115Chemical Co (Madrid, Spain) or from Merck (Darm-
stadt, Germany).
2.2. Cell culture
The fetal mouse skin dendritic cell line (FSDC),
established from fetal mouse skin suspensions
[33], was kindly supplied by Dr. G. Girolomoni.
The cells were maintained at 37 8C, in a humidified
atmosphere at 95% air and 5% CO2, in Iscovemodified
Dulbecco’s medium (Sigma) supplemented with 10%
heat inactivated fetal calf serum, 36 mM sodium
bicarbonate, 64.4 mM glutamine, 100 U/ml penicil-
lin and 100 mg/ml streptomycin. Cells were fed with
fresh medium every 2—3 days.
2.3. Stimulation with chemicals
Cells were plated at 0.69  106 cells/well, in 6-well
microplates, for Western blot analysis, and at
0.4  106 cells/well, on glass coverslips, for immu-
nocytochemistry assays, and were grown for 2 days.
The cells were then placed in serum-free Iscove
modified Dulbecco’s medium (IMDM) for 10—
30 min before addition of the strong sensitizer
DNFB, at 5 mg/ml. Cells were then kept at 37 8C
for different periods of time, as indicated in the
figure captions. SB203580 (20 mM) or SB202190
(10 mM) were used as inhibitors of p38 MAPK, and
U0126 (5 mM) and PD 98059 (40 mM) as inhibitors of
the ERK 1/2 pathway. In this case, cells were pre-
incubated with the inhibitors for 1h before stimula-
tion with the sensitizer DNFB for 2 h.
2.4. Cell lysate preparation
In order to prepare cell extracts for Western blot
analysis, after stimulation (as described above) the
cells were washed with ice-cold PBS and scraped
into ice-cold lysis buffer containing protease and
phosphatase inhibitors (50 mM Hepes pH 7.5, 1%
Triton X-100, 100 mM NaCl, 2 mM EGTA, 2 mM EDTA,
2 mM Na3VO4, and freshly added 1 mM PMSF, 2.5 mg/
ml Pepstatin, 1 mM DTT, 10 mM E64, 20 mg/ml Ben-
zamidin, 10 mM NaF). Cell lysates were clarified by
centrifugation at 9700  g, for 30 min, at 4 8C. The
supernatants were stored at 80 8C until protein
determination using the BCA protein assay method
(Pierce, Rockford, IL). Cell lysates were then boiled
for 5 min in 6 sample buffer (187.5 mM Tris—HCl pH
6.8; 12% w/v SDS; 60% sucrose; 0.06% bromophenol
Blue and 37.5% b-mercaptoethanol) and either used
immediately for SDS/PAGE electrophoresis or frozen
at 20 8C until use. Cell lysates for anti-CD40 Wes-
tern blots were prepared with the same solutions
but without the reducing agent, DTT.2.5. Western blot analysis
Western blot was performed for the analysis of ERK,
JNK and p38 MAPK activation (using antibodies spe-
cific for the phosphorylated form of the three
kinases) and for the analysis of CD40 protein levels.
Briefly, equivalent amounts of protein (25—40 mg)
were loaded onto a 10% SDS-polyacrylamide gel,
subjected to electrophoresis, and transferred to
polyvinylidene difluoride (PVDF) membranes (Amer-
sham Biosciences). The membranes were saturated
with 5% (w/v) fat—free dry milk in Tris—buffered
saline (50 mM Tris, pH 8.0, 150 mM NaCl) with 0.1%
Tween 20 (TBS-T), for 90 min, at room temperature,
or overnight at 4 8C (for JNK). Blots were then
incubated overnight with primary antibodies at
1:1000 or 1:5000 dilution, for phospho-p38 MAPK
and -ERK, respectively. Incubation with the antibo-
dies against CD40 (1:500) and phospho-JNK (1:5000)
was performed for 2 h, at room temperature. The
solutions of primary antibodies were prepared in 1%
fat free dry milk in TBS-T. After extensive washing
with 0.5% fat free dry milk in TBS-T solution, blots
were further incubated for 1h at room temperature
with goat anti-rabbit or anti-rat IgG antibodies
coupled to alkaline phosphatase, at 1:20,000 or
1:10,000 dilution, respectively, in 1% fat free dry
milk in TBS-T. Blots were then washed in 0.5% fat
free dry milk in TBS-T. The immune complexes were
detected using the ECF system (Amersham Bios-
ciences), and the membranes were then scanned
with Blue excited fluorescence on the Storm 860
(Amersham Biosciences) according to the manufac-
turers instructions. The signals were analyzed using
the ImageQuant software (Amersham Biosciences).
2.6. Immunocytochemistry assays
FSDCs, stimulated as described above, were rinsed
with PBS and fixed and permeabilized with metha-
nol:acetone (1:1), for 10 min (for ERK 1/2 detec-
tion), or with methanol, for 5 min (for p38 MAPK
detection), at 20 8C. Non-specific binding was
blocked by incubation with 20% (or 10% for phos-
pho-p38 MAPK) normal goat serum in PBS, for 1 h at
room temperature. Coverslips were then incubated
overnight at 4 8C with the primary antibody (anti-
phospho-ERK1/2, diluted 1:100, or anti-phospho-p38
MAPK, diluted 1:200) in PBS supplemented with 5%
(or 1.5% for phospho-p38 MAPK) normal goat serum.
The cells were then rinsed, for 15 min, in six changes
of PBS, and incubated, for 90 min, at room tempera-
ture, with the secondary antibody (Alexa 488-con-
jugated goat anti-rabbit antibody, diluted 1:2000) in
PBS supplemented with 1% (or 1.5% for p38 MAPK)
normal goat serum. After rinsing the coverslips as
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Fig. 1 DNFB induces a dose-dependent phosphorylation
of ERK, JNK and p38 MAPK in FSDC cells. Cells were
stimulated or not with DNFB, at the indicated concentra-
tions, during 30 min. Equal amounts of protein were
loaded on 10% SDS-polyacrylamide gels and subjected
to electrophoresis and electrotransferred to PVDF mem-
branes, before probing with phospho-specific anti-ERK1/2
(A), anti-JNK (B) or anti-p38 MAPK (C) antibodies, as
described in Section 2. The results were quantified by
scanning the membrane with a fluorescence scanner and
analyzed using the ImageQuant software. The results were
expressed as the % of phosphorylation relatively to total inbefore, they were mounted onto a slide with the
Prolong antifade kit to reduce the photobleaching of
the fluorescent dye. Negative control experiments
were done, consisting on processing the same pre-
paration as described, except for the omission of the
primary antibody, and resulted in no non-specific
staining. Fluorescent labeling was visualized by con-
focal microscopy, using a MRC600 confocal system
(BIORAD Laboratories, Milan, Italy) linked to a Nikon
Optiphot-2 fluorescence microscope, using a 60
immersion oil objective. A Krypton/Argon mixed
laser was used in combination with a fluorescein
filter. Image processing included a Kadman filter,
using confocal assistant software.
2.7. Data analysis
The results are expressed as mean  SEM of the
indicated number of independent experiments, and
statistical analysis was performed using the One-Way
ANOVA test, with a Dunnett’s post-test or the
Repeated measures ANOVA with a Bonferroni’s
post-test, as indicated. A difference with p value
< 0.05 was considered statistically significant.3. Results
3.1. Differential effect of DNFB on the
activation of MAPKs
In order to access which signal transduction path-
ways are activated by DNFB, we examined the con-
tent on phosphorylated ERK1 (p44)/ERK2 (p42), p38
MAPK and JNK in FSDC stimulated with different
concentrations of DNFB (1—1000 mg/ml), using anti-
bodies raised against the dually phosphorylated
(active) form of the enzymes. High doses of DNFB
(1 mg/ml) induced phosphorylation of the three
MAPKs (Fig. 1). However, for lower doses of DNFB,
only ERK1/2 and p38 MAPK were found to be phos-
phorylated. The maximal effect on ERK1/2 phos-
phorylation was observed for 100 mg/ml (Fig. 1A),
whereas DNFB induced a strong phosphorylation of
p38 MAPK only at 5 or 10 mg/ml (Fig. 1C). Since DNFB
at concentrations higher than 5 mg/ml reduce the
viability of the cells as evaluated by the MTT assay
[34] (data not shown), all subsequent studies were
performed using 5 mg/ml of DNFB.each experiment. Data are expressed as the mean  SEM
of three independent experiments. Statistical significance
was calculated by the One-Way ANOVA test with a Dun-
nett’s post-test (*p < 0.05; **p < 0.01 as compared to the
control; ++p < 0.01 as compared to the control ERK1
phosphorylation (A)).
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by DNFB with different kinetics
The time course of ERK1/2 and p38 MAPK phosphor-
ylation was determined in order to investigateFig. 2 DNFB induces a time-dependent increase of
ERK1/2 and p38 MAPK phosphorylation in FSDC cells. Cells
were stimulated, or not, with 5 mg/ml of DNFB and the
cell lysates were collected at the indicated times after
stimulation. Equal amounts of protein were loaded on 10%
SDS-polyacrylamide gels, subjected to electrophoresis
and electrotransferred to PVDF membranes, before prob-
ing with a phospho-specific anti-ERK1/2 antibody (A) or
anti-p38 MAPK antibody (B), as described in Section 2. The
results were quantified by scanning the membrane with a
fluorescence scanner and analyzed using the ImageQuant
software. The results were expressed as the % of phos-
phorylation relatively to total in each experiment. Data
are expressed as the mean  SEM of four independent
experiments. Statistical significance was calculated by
the One-Way ANOVA test with a Dunnett’s post-test
(*p < 0.05; **p < 0.01 as compared to the control;
+p < 0.05, ++p < 0.01 as compared to the control ERK1
phosphorylation (A)).whether the activation of MAPKs by DNFB occurred
with similar kinetics. FSDC cells were stimulated
with DNFB for different periods of time and phos-
phorylation of the MAPKs was examined by Western
blot analysis (Fig. 2). ERK1/2 phosphorylation (acti-
vation) was detected as soon as 1 min after exposure
to DNFB (Fig. 2A). The ERK1 (44 kDa) activation
induced by DNFB was biphasic, with a rapid and
transient phosphorylation (activation) that peaked
around 1—5 min, followed by a second phase of
kinase activity at 30—45 min. The kinetics of ERK2
(42 kDa) phosphorylation followed a distinct pat-
tern. After the first minute of stimulation, ERK2
phosphorylation showed a slight increase relatively
to the control, which however did not reach statis-
tical significance, in contrast with the results
obtained for ERK1. The delayed response (45 min)
was similar for both isoforms of ERK, but ERK2
phosphorylation was much stronger.
p38 MAPK showed a slower kinetics of phosphor-
ylation, starting at 15 min of stimulation and reach-
ing the maximal increase within 30—45 min of
stimulation with DNFB (Fig. 2B). Taken together,
our results indicate that both ERK1/2 and p38 MAPK
are phosphorylated upon DNFB stimulation,
although with different kinetics.
The specificity of the sensitizing effect of DNFB
was tested using its structurally related analogue
DCNB, which has no [35] or very low [36] skin
sensitization potential. In contrast with the results
observed with DNFB, DCNB did not affect the phos-
phorylation of ERK1/2 or p38 MAPK (Fig. 3A and B).
Therefore, our data indicate that the effect
observed with DNFB is specific of its allergenic
property.Fig. 3 DCNB, the inactive analogue of DNFB, does not
affect ERK1/2 and p38 MAPK phosphorylation. Cells were
stimulatedornotwith 5 mg/ml ofDCNBorDNFBand thecell
lysates were collected at the indicated times after stimula-
tion. Equal amounts of protein were loaded on 10% SDS-
polyacrylamide gels, subjected to electrophoresis and
electrotransferred to PVDF membranes, before probing
with a phospho-specific anti-ERK1/2 antibody (A) or anti-
p38 MAPK antibody (B), as described in Section 2. Data are
representative of three independent experiments.
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of activated ERK 1/2 and p38 MAPK
Since the phosphorylation of MAPKs is frequently
associated with their translocation to the nucleusFig. 4 DNFB-induced activation and translocation of ERK1/2
not with DNFB (5 mg/ml), and immunostained with phospho-sp
described in Section 2. The figures are representative of the re[25], immunocytochemistry experiments were per-
formed to determine the effect of DNFB on their
subcellular location (Fig. 4). Control cells, not incu-
bated with DNFB, showed low immunoreactivity
with the phospho-specific anti-active ERK1/2 anti-and p38 MAPK to the nucleus. The cells were stimulated or
ecific anti-ERK1/2 (A) or anti-p38 MAPK (B) antibodies, as
sults obtained in at least three independent experiments.
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Fig. 5 DNFB, but not DCNB, increases CD40 protein
levels in FSDC. Cells were stimulated or not with 5 mg/
ml DNFB or DCNB. Cell lysates were collected at the
indicated times after stimulation. Equal amounts of pro-
tein were loaded on 10% SDS-polyacrylamide gels, sub-
jected to electrophoresis and electrotransferred to PVDF
membranes, before probing with an anti-CD40 antibody
(A). The results were quantified by scanning the mem-
brane with a fluorescence scanner and analyzed using the
ImageQuant software. The results were expressed as fold
increase relatively to the control in each experiment (B).
Data are expressed as the mean  SEM of four indepen-
dent experiments. Statistical significance was calculated
by the One-Way ANOVA test with a Dunnett’s post-test
(*p < 0.05; **p < 0.01 as compared to the control).body (Fig. 4A), indicating that there is a minor
resting activity of ERK1/2 in the cytosol. Transloca-
tion of pERK1/2 to the nucleus was observed after
5 min of stimulation with DNFB and was maintained
over 15 min. After 30 min of stimulation p-ERK1/2
was still found in the cytosol. In contrast, DNFB
increased the amount of phosphorylated p38 MAPK
in the nucleus only after 30 min of stimulation
(Fig. 4B). These results demonstrate that in FSDC
the two MAPK pathways are activated by DNFB,
although with a different time course. Their trans-
location to the nucleus, confirmed by these obser-
vations, suggests that these signaling molecules may
be involved in the regulation of nuclear proteins by
DNFB, namely transcription factors.
3.4. DNFB-induced an increase of CD40
immunoreactivity
Protein levels of CD40, a surface marker related
with the maturation and activation of DC, were
measured after stimulation of FSDC with DNFB.
Using an antibody that recognizes CD40, we
observed that CD40 protein levels are low in resting
FSDC, but increase significantly upon stimulation
with DNFB (Fig. 5). This increase was detected after
30 min of stimulation (2.5-fold above control) and
further increased until 3—8 h of incubation with the
sensitizer. Similar results were obtained when the
cells were stimulated with DNFB in culture medium
containing serum (not shown). In contrast with the
results obtained with DNFB, CD40 protein levels
were not affected by DCNB (Fig. 5).
3.5. DNFB-inducedCD40immunoreactivity
is partially dependent on the activation
of p38 MAPK
In order to investigate the role of ERK1/2 and p38
MAPK pathways on the activation and maturation
of FSDC, we studied the effect of MEK and p38
MAPK inhibitors on the expression of CD40. The
effect of DNFB on CD40 protein levels was not
changed in the presence of the MEK inhibitors
PD098059 and U0126 [37,38] (Fig. 6A). In contrast,
the p38 MAPK inhibitors, SB203580 [39] and
SB202190 [37], partly reduced the effect of the
sensitizer on CD40 protein levels after 2 h of sti-
mulation (Fig. 6B). Although the effect was very
consistent in all the experiments performed the
inhibition of DNFB-induced CD40 upregulation did
not reach statistical significance. These results
suggest that activation of p38 MAPK, but not
ERK1/2, is involved in the upregulation of CD40
protein levels induced by DNFB in FSDC, but it is
not the main signaling pathway involved.4. Discussion
The major cellular events involved in the matura-
tion and migration of DC to lymph nodes during the
process of skin sensitization are still unknown. In the
present work, we show that while high doses of the
chemical sensitizer DNFB induced the activation of
the three MAPK family members, ERK, JNK and p38
MAPK, only ERK1/2 and p38 MAPK were activated in
a skin-derived dendritic cell line (FSDC) by subtoxic
concentrations of the sensitizer. Furthermore, DNFB
also increased CD40 protein levels in FSDC by a
mechanism largely independent of the MAPK signal-
ing pathways.
ERKs are found in different subcellular compart-
ments, phosphorylating a wide range of proteins,
from the plasma membrane to the nucleus. These
proteins of the MAPK family have been shown to play
important roles in cell growth and differentiation
[20,23], cell survival and in inflammatory responses
[22,40—42]. In the present study, we found that
DNFB has a biphasic effect on ERK1/2 activity in
the cells: a rapid activation of ERK1 (within 1 min)
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Fig. 6 p38 MAPK, but not ERK, is partially involved in DNFB induced increase of CD40 protein levels in FSDC. To access
the involvement of ERK1/2 or p38 MAPK in the increase of CD40 protein levels, cells were stimulated or not with 5 mg/ml
DNFB in the presence of MEK inhibitors (PD 98059 (40 mM) or U0126 (5 mM)) (A) or in the presence of p38 MAPK inhibitors
(SB203580 (20 mM) or SB202190 (10 mM)) (B), and collected after 2 h of stimulation. Equal amounts of protein were loaded
on 10% SDS-polyacrylamide gels, subjected to electrophoresis and electrotransferred to PVDF membranes, before
probing with an anti-CD40 antibody. The results were quantified by scanning the membrane with a fluorescence scanner
and analyzed using the ImageQuant software. The results were expressed as fold increase relatively to the control in each
experiment. Data are expressed as the mean  SEM of four independent experiments. Statistical significance was
calculated by the Repeated measures ANOVA test with a Bonferroni’s post-test (*p < 0.05; **p < 0.01 as compared to the
control).and a further increase until 5 min of stimulation
(Fig. 2A), which occurred in parallel with ERK trans-
location to the nucleus in FSDC (Fig. 4A). Once in the
nucleus ERK1/2 are likely to be involved in the
regulation of transcription factors [27,43], namely
NF-kB, that we have previously shown to be acti-
vated by DNFB at 15 min in these cells [44]. The
nuclear translocation of the phosphorylated ERK1/2
is in agreement with previous work performed in
other cell types [22,25]. In a second phase, a
delayed increase in ERK1 activity was observed after
30—45 min stimulation. This second increase in ERK1
activity was accompanied by an increase in ERK2
activity (Fig. 2A), and was characterized by a strong
immunoreactivity in the cytoplasm (Fig. 4A). The
difference observed in the activation of the two ERK
isoforms suggests that they may mediate different
processes.
Previous studies using LPS, an immunostimulatory
molecule which also induces the maturation of DCs
by binding to receptor molecules at the cell surface,
also showed activation of ERK1/2 in macrophages
and DCs, although with a different kinetic [42,45]. Inthe latter cell type the activation of ERK1/2 by LPS
was involved in the regulation of cell survival [42].
Additionally, in murine B cells it was further demon-
strated that stimulation with two distinct agents
(CD40 and IgM) differentially regulates ERK subcel-
lular localization, supporting the notion that ERK
could mediate different effector functions in these
cells upon stimulation with different agents [46].
Therefore, the differential activation of ERK1 and
ERK2 in FSDC stimulated with DNFB may also cause
distinct functional responses in the cell.
p38 MAPK, together with JNK, are considered
stress activated kinases, and p38 MAPK has also
been implicated in the inflammatory response
[20,22,26,47]. Here we observed that DNFB induced
activation of p38 MAPK after a lag-phase of about
15 min, and the activity of the kinase further
increased until 45 min of incubation (Fig. 2B).
Furthermore, the phosphorylated form of p38 MAPK
was translocated to the nucleus in a significant
number of cells after 30 min stimulation with DNFB,
as determined by immunocytochemistry (Fig. 4B).
Our findings are in agreement with recent reports
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cyte-derived dendritic cells stimulated with DNFB
[30] or 2,4-dinitrochlorobenzene (DNCB, which has a
similar sensitizing potential as DNFB) [29]. However,
in the former study the activation of p38 MAPK was
observed for shorter incubation periods. Further-
more, we also detected a strong activation of ERK1/
2 by DNFB, which was not observed by Arrighi et al.
[30]. In experiments using humanmonocyte-derived
DCs these two signaling pathways were also shown
to be activated by another skin sensitizer — NiCl2 —
[29], which, as we have shown for DNFB [44], also
activates the NF-kB transcription factor [29]. The
activation of p38 MAPK by DNCB was also recently
observed using an immature murine dendritic cell
line (BC1 cells) [32]. In contrast, and in agreement
with other reports [29,30], we observed that a non-
sensitizer, DCNB (an inactive analogue of DNFB), did
not activate any of the MAPKs.
Several reports using immunostimulatory mole-
cules, such as LPS, that also promotes DC matura-
tion, also described an increase of p38 MAPK and ERK
in dendritic cells [28—30,48]. Also, using a p38 MAPK
inhibitor, we have previously shown that this path-
way is involved in NO production induced by LPS in
FSDC [49]. Taken together, these findings suggest
that the signaling pathways described here are
shared by chemical sensitizers and immunostimula-
tory molecules.
We further studied the effect of DNFB on the
expression of CD40, a membrane-associated recep-
tor that is upregulated in DCs during maturation
induced by several stimuli, including skin sensiti-
zers. The results show that CD40 protein levels are
upregulated in FSDC as soon as 30 min after DNFB
stimulation and further increased during the time of
the experiment, whereas the non-sensitizer DCNB
had no effect. In preliminary experiments we found
that DNFB also slightly upregulated CD80 and CD86
protein levels, but the effects were not as signifi-
cant as those obtained for CD40 (unpublished obser-
vations).
ERK and, specially, p38 MAPK activation, seem to
be involved in the maturation of DCs, namely in
increasing the expression of costimulatory mole-
cules [28—30,48]. However, in the present work
we observed that only p38 MAPK inhibitors showed
a slight effect on DNFB-induced upregulation of
CD40, suggesting that other signaling pathways
are also involved. p38 MAPK was shown to be
involved in CD40 upregulation induced by LPS [30]
and by plasmin [50], but a role for p38 MAPK in CD40
upregulation induced by skin sensitizers had not
been described. In our work, the decrease in
CD40 protein levels detected in the presence of
p38 MAPK inhibitors was not statistically significant,indicating that this kinase is not the main signaling
pathway involved in CD40 upregulation induced by
DNFB in FSDC.
Although in FSDC stimulated with DNFB we
detected both the activation of MAPKs in FSDC
and an increase in CD40, only p38 MAPK could be
slightly correlated with the regulation of CD40 pro-
tein levels. Therefore, the role of ERK and p38 MAPK
activation in the maturation of FSDC remains to be
assessed. The translocation of both ERK1/2 and p38
MAPK to the nucleus suggests that they are involved
in the regulation of transcription factors that may
contribute to FSDC maturation. Interestingly, in
monocyte-derived DCs stimulated with LPS and
TNF-a, the ERK pathway has been described as a
negative regulator of DC maturation, opposing to
the p38 MAPK pathway [51].
In conclusion, DNFB induced the activation of
ERK1/2 and p38 MAPK in FSDC, as well as the upre-
gulation of CD40 expression, whereas its inactive
analogue DCNB did not. This indicates that this
strong sensitizer induces phenotypical changes that
may represent an early activation state of the DCs,
which could be responsible for the sensitization
phase of ACD. Furthermore, p38 MAPK seems to
have a minor role in the upregulation of CD40
expression, suggesting that the MAPKs signaling
pathways are involved in other processes that
remain to be identified.
Studies of the intracellular signaling pathways
used by allergens to activate DC and to promote
their presentation to the immune system, and of
how pharmacological tools interfere with these
pathways, are very relevant to the understanding
of the physiopathology of allergic contact dermatitis
and its treatment. If data on different skin sensiti-
zers proves to be reproducible, in vitro DC activation
can be used to study the sensitization potential of
chemicals applied to the skin, instead of using living
animals for LLNA.Acknowledgements
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